19064-24-5

Basic information

• Product Name: 2,6-Difluoronitrobenzene
• Synonyms: 1,3-DIFLUORO-2-NITROBENZENE;2,6-DIFLUORONITROBENZENE;Benzene, 1,3-difluoro-2-nitro- (8CI,9CI);2,6-Difluoronitrobenzene 98%;2,6-Difluoronitrobenzene98%;2,6-Difluoro-1-nitrobenzene;2,6-Difluoronitroben;1,3-Difluoro-2-nitrobenzene2,6-difluoronitrobenzene
• CAS NO: 19064-24-5
• Molecular Formula: C6H3F2NO2
• Molecular Weight: 159.09
• EINECS: 242-793-8
• Product Categories: HALIDE;Aromatic Hydrocarbons (substituted) & Derivatives;Nitro Compounds;Nitrogen Compounds;Organic Building Blocks
• Mol File: 19064-24-5.mol
• Article Data: 10

Chemical Properties

• Melting Point: 0C
• Boiling Point: 91-92 °C11 mm Hg(lit.)
• Flash Point: 190 °F
• Appearance: White liquid with light yellow
• Density: 1.503 g/mL at 25 °C(lit.)
• Refractive Index: n20/D 1.494(lit.)
• Storage Temp.: Inert atmosphere,Room Temperature
• Water Solubility: Slightly soluble in water.
• CAS DataBase Reference: 2,6-Difluoronitrobenzene(CAS DataBase Reference)
• NIST Chemistry Reference: 2,6-Difluoronitrobenzene(19064-24-5)
• EPA Substance Registry System: 2,6-Difluoronitrobenzene(19064-24-5)

Safety Data

• Hazard Codes: Xi
• Statements: 10-36/37/38
• Safety Statements: 16-26-36-37/39
• WGK Germany: 3
• Hazardous Substances Data: 19064-24-5(Hazardous Substances Data)

Usage

Uses

Different sources of media describe the Uses of 19064-24-5 differently. You can refer to the following data:
1. 1,3-Difluoro-2-nitrobenzene is a useful chemical reagent.
2. 2,6-Difluoronitrobenzene may be used in the preparation of secondary amine precursors, required for the synthesis of two families of nitric oxide donors.

Chemical Properties

Light yellow to dark yellow solid

General Description

2,6-Difluoronitrobenzene is an organic building block. Molecular structure, conformation and potential to internal rotation of 2,6-difluoronitrobenzene been studied by gas-phase electron diffraction (GED), MP2 ab initio, and by B3LYP density functional calculations.

InChI:InChI=1/CH3NO.F6P/c1-2-3;1-7(2,3,4,5)6/h2H,1H2;/q+1;-1

Upstream product

• 5509-65-9 2,6-difluoroaniline 
• 74087-85-7 3,3-dimethyldioxirane 
• 541-73-1 1,3-Dichlorobenzene 
• 121-73-3 3-Nitrochlorobenzene 
• 29270-54-0 1,3-difluoro-2-nitrosobenzene 
• 133117-48-3 1,3-difluoro-2-trimethylsilylbenzene 
• 98-95-3 nitrobenzene 

Downstream Products

• 385-01-3 2-nitro-3-fluorophenol 
• 305811-06-7 2-methylmercapto-6-fluoronitrobenzene 
• 915135-20-5 tert-butyl 4-(3-fluoro-2-nitrophenyl)piperazine-1-carboxylate 
• 641-49-6 1-fluoro-3-methoxy-2-nitrobenzene 
• 98968-78-6 2-(2-chloro-4-trifluoromethylphenoxy)-6-fluoro nitrobenzene 
• 920284-79-3 1-(benzyloxy)-3-fluoro-2-nitrobenzene 
• 866082-35-1 C₁₆H₁₄FNO₅ 
• 872141-24-7 2-(3-fluoro-2-nitrophenyl)malonic acid dimethyl ester 
• 500302-19-2 (3-fluoro-2-nitro-phenyl)-(3-fluoro-phenyl)-amine 
• 288580-60-9 tert-butyl (3,5-difluoro-4-nitrophenyl)acetate 
• 929565-65-1 (3-Fluoro-2-nitro-phenyl)-(2-fluoro-phenyl)-amine 
• 1159999-75-3 ¹N,³N-dioctyl-2-nitrobenzene-1,3-diamine 
• 908590-74-9 N,N'-diethyl-2-nitrobenzene-1,3-diamine 
• 866211-61-2 (3-fluoro-2-nitro-phenyl)-isopropyl-amine 

Relevant articles and documents

Pseudocyclic bis-N-heterocycle-stabilized iodanes - synthesis, characterization and applications

Bis-N-heterocycle-stabilized λ3-iodanes (BNHIs) based on azoles are introduced as novel structural motifs in hypervalent iodine chemistry. A performance test in a variety of benchmark reactions including sulfoxidations and phenol dearomatizations revealed a bis-N-bound pyrazole substituted BNHI as the most reactive derivative. Its solid-state structure was characterizedviaX-ray analysis implying strong intramolecular interactions between the pyrazole nitrogen atoms and the hypervalent iodine centre.

DIHYDROBENZOFURANYL DERIVATIVES AND METHODS OF THEIR USE

The present invention is directed to dihydrobenzofuranyl derivatives of formula I: or a pharmaceutically acceptable salt thereof, which are monoamine reuptake inhibitors, compositions containing these derivatives, and methods of their use for the prevention and treatment of conditions, including, inter alia, vasomotor symptoms sexual dysfunction, gastrointestinal disorders and genitourinary disorder, depression disorders, endogenous behavioral disorder, cognitive disorder, diabetic neuropathy, pain, and other diseases or disorders.

Progesterone receptor antagonists, contraceptive regimens, and kits

A method of contraception is provided which involves delivery of 21 to 27 consecutive days of one or more PR antagonists in the absence of a progestin, estrogen, or other steroidal compound, followed by 1 to 7 days without any active agent. Also described is a pharmaceutically useful kit to facilitate delivery of this regimen.